Olema Oncology to Present Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting

Core Insights - Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer and will present two preclinical posters at the AACR Annual Meeting in April 2026 [1][2] Group 1: Poster Presentation Details - The first poster titled "Palazestrant directly recruits the corepressor protein NCoR1 in vitro leading to complete antagonism of estrogen receptor alpha" will be presented on April 20, 2026, from 2:00-5:00pm PT [2] - The second poster titled "Palazestrant, a CERAN, in combination with OP-3136, a KAT6 inhibitor, synergistically downregulates cell proliferation and metastasis related gene signatures" will also be presented on April 20, 2026, from 2:00-5:00pm PT [2] Group 2: Company Overview - Olema Oncology is committed to transforming the standard of care for patients with breast cancer, advancing a pipeline of novel therapies based on a deep understanding of endocrine-driven cancers [3] - The lead product candidate, palazestrant (OP-1250), is currently in two Phase 3 clinical trials and is a proprietary, orally available complete estrogen receptor antagonist and selective estrogen receptor degrader [3][4] - OP-3136, another candidate, is a potent KAT6 inhibitor currently in a Phase 1 clinical study, having shown significant anti-proliferative activity in ER+ breast cancer models [5]